All In Biotech

Drug Trial Radar · NCT06692283

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Denifanstat in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MALSD)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Last checked: Nov 19, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

WithdrawnPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 2025

Primary completion

Jun 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Sagimet Biosciences Inc.Industry
Sponsor type
Industry
First posted
Nov 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of denifanstat 50 mg compared to placebo in patients with metabolic dysfunction-associated steatotic liver disease (MALSD)/metabolic dysfunction-associated steatohepatitis (MASH) after 52 weeks of treatment.

Conditions

  • MASLD
  • MASH
  • NASH
  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Metabolic Dysfunction-Associated Steatohepatitis
  • Nonalcoholic Steatohepatitis
  • Nonalcoholic Fatty Liver

Interventions

  • denifanstatDrug

    Tablet

  • PlaceboDrug

    Matching tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety Outcome Measure: TEAEsTime frame: 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.